Krishan Thirunavukkarasu

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 395 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

Paul Bird, Stephen Hall, Peter Nash et al. · RMD Open · 2019 · 53 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice

Lynda Spelman, John Su, Pablo Fernández‐Peñas et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 28 citations

Medicine, Clinical Sciences, Dermatology +10

Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in australian patients: A cross-sectional, multicenter study

Lachlan Standfield, Sarah Norris, Charles Harvey et al. · Clinical Therapeutics · 2010 · 16 citations

Pharmacy, Health Sciences, Health Services Research +16

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

Stephen Hall, Peter Nash, Maureen Rischmueller et al. · Rheumatology and Therapy · 2018 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17